Jazz Pharmaceuticals PLC'srelease ofpositive data for its JZP-110 in two Phase III studies boosts prospects for the drug, keeping it on track for a filing in obstructive sleep apnea and narcolepsy in late 2017.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?